Barry McCleney, MD
Family Medicine · Springville, ALNPI 1467514687
Payments from drug & device makers
Across 307 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$789
- Paratek Pharmaceuticals, Inc.$615
- Pfizer$492
- AstraZeneca$420
- Otsuka America Pharmaceutical, Inc.$396
- AbbVie$269
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,56498%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 50 | $789 |
| Paratek Pharmaceuticals, Inc. | 30 | $615 |
| Pfizer | 33 | $492 |
| AstraZeneca | 22 | $420 |
| Otsuka America Pharmaceutical, Inc. | 13 | $396 |
| AbbVie | 23 | $269 |
| Lilly USA, LLC | 14 | $226 |
| Merck | 13 | $219 |
| Exact Sciences | 12 | $211 |
| Amarin Pharma, Inc. | 13 | $208 |
| Dexcom, Inc. | 4 | $175 |
| Johnson & Johnson | 2 | $138 |
| Novo Nordisk | 8 | $137 |
| Sumitomo Pharma America, Inc. | 6 | $135 |
| Amgen | 7 | $121 |
| Boehringer Ingelheim | 7 | $118 |
| Astellas Pharma US Inc | 2 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Bayer | 4 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $82 |
| Boston Scientific | 3 | $67 |
| IBSA Pharma Inc. | 4 | $67 |
| Lundbeck LLC | 2 | $44 |
| Novartis | 2 | $41 |
| Biogen | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| Medtronic | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| PBG Puerto Rico LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$233
- XARELTO$123
- REXULTI$121
- DEXCOM G6 TRANSMITTER$113
How this compares
$5,664 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 140 | $167,631 |
| OzempicSemaglutide | 150 | $157,614 |
| EliquisApixaban | 180 | $151,311 |
| NuzyraOmadacycline Tosylate | 12 | $89,155 |
| JardianceEmpagliflozin | 96 | $76,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $65,905 |
| FarxigaDapagliflozin Propanediol | 76 | $61,055 |
| TrulicityDulaglutide | 56 | $59,366 |
| JanuviaSitagliptin Phosphate | 50 | $37,611 |
| MyrbetriqMirabegron | 37 | $30,665 |
| LinzessLinaclotide | 47 | $29,225 |
| EntrestoSacubitril/Valsartan | 22 | $21,233 |
| TradjentaLinagliptin | 27 | $20,289 |
| CreonLipase/Protease/Amylase | 13 | $20,187 |
| VraylarCariprazine Hcl | 13 | $18,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $226 | $226,997196 claims |
| Novo NordiskOzempic, Levemir | $137 | $162,757166 claims |
| PfizerEliquis | $492 | $151,311180 claims |
| Boehringer IngelheimJardiance, Tradjenta | $118 | $97,107123 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $615 | $89,15512 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $420 | $77,85597 claims |
| AbbVieLinzess, Creon, Vraylar | $269 | $67,91373 claims |
| GSKTrelegy Ellipta | $789 | $65,90581 claims |
| MerckJanuvia, Lagevrio (Eua) | $219 | $46,24563 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $30,66537 claims |
| NovartisEntresto | $41 | $21,23322 claims |
| Johnson & JohnsonXarelto | $138 | $16,07821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Springville
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.